The Company Chemists' Association (CCA) says the data from the 'Locate a Locum's annual report' has revealed that the average locum rate rose by 124 per cent
in Scotland in 2021 compared to the previous year and that the trend seems to have continued since.
According to the report, in Scotland, the average rate has risen from £20.08 to £44.89 which is a massive £24.81 difference.
This was in response to the pharmacists Defence Association (PDA)'s statement on 15 times more closure of pharmacy in Scotland by a CCA member.
"This clearly demonstrates that demand for pharmacists in Scotland is outstripping supply," said the association.
Explaining further, it said: "Our members have been serving Scottish communities and patients without issue for decades. Recent pressures, however, are unprecedented.
Workforce challenges are affecting all parts of healthcare across the UK - and community pharmacy is no different. Pharmacists remain on the Home Office's shortage
occupation list for this reason."
Calls have been made for more pharmacies to help with the rollout of the county's coronavirus booster jabs.
Around 25 pharmacies in Kent and Medway have been distributing vaccines to thousands of patients.
This represents just seven per cent of the 320 pharmacies in the county.
The call comes despite staff shortages and growing workload pressures, such as carrying out non-essential tasks, which include patient satisfaction surveys.
Shilpa Shah, the chief executive officer at the Kent Local Pharmaceutical Committee, said: "We have workforce issues, but are pulling together to deliver essential patient services and Covid vaccinations at the same time."
Pharmacies are one of several health organisations working hard to ensure that everyone aged 18 and over will be offered a booster vaccination by the target of January 31, which has been set by the government.
National Pharmacy Association (NPA) urged the NHS England to make local impact assessment a key requirement prior to any recruitment into Primary Care Networks (PCNs) and Clinical Commissioning Groups (CCGs), to help tackle workforce crisis.
With inputs from LPCs, PCNs and CCGs should consider the impact of the creation of new roles on all health care providers in the area and on their ability to deliver their objectives on behalf of the NHS, it said.
The NPA believes that creation of the Additional Roles Reimbursement Scheme (ARRS) programme is impacting community pharmacy services in some areas and contributing to the ongoing workforce shortage.
In a letter addressed to Ed Waller, director of Primary Care for NHS England, NPA chief executive Mark Lyonette highlighted the challenges emerged following a shortage of pharmacists and other members of staff.
The Pharmacists' Defence Association (PDA) has launched a brutal attack on some large pharmacy chains for full or part-day closures of some of their shops
throughout the UK.
It published an Open Letter on Tuesday (July 19) demanding urgent action "to protect patients by ensuring that essential community pharmacy services are provided
safely and consistently".
PDA chair Mark Koizol, who wrote the letter, went on to allege that many of those closure were "being orchestrated".
He wrote that the "pharmacist shortage" narrative cited as a reason for these closures was "very different" from "the reality experienced by our members", including
both employed and locum pharmacists.
"We have evidence to show that these closures are being announced up to four weeks in advance," Koizol claimed.
He gave examples of how a large company attempted to reduce the pre-agreed rate of locums and where this was not accepted, the shift was cancelled, resulting in the
pharmacy being closed for part or full day.
The General Pharmaceutical Council (GPhC) and the Chief Pharmaceutical Officer for England have written a letter to pharmacy professionals thanking them for
providing the best possible services to patients and the public, despite experiencing high and sustained demands and pressures.
GPhC Chief Executive Duncan Rudkin and CPhO David Webb indicated that there will be further challenges over the coming weeks and months due to the ongoing industrial
action, and staff shortages due to sickness or caring responsibilities.
They expressed concerned that increased pressure will have a significant and potentially prolonged impact on pharmacy teams both personally and professionally.
Acknowledging that pharmacy professionals may have to make some difficult decisions as they deal with the pressures they face, the leaders have urged those working
in pharmacy to use "your professional judgement to assess and mitigate risk, and to deliver safe and effective care for your patients within your scope of practice."
Health and Social Care Secretary Sajid Javid and Madelaine McTernan, head of the HRT supply taskforce, continue to take urgent action to resolve the shortage of HRT medicines by meeting the drug manufacturers and representatives from community pharmacies on Thursday (May 5).
In the meeting, manufacturers outlined the steps they're taking to boost supply, and pharmacists shared their experiences on the frontline, as well as sharing their
thoughts on wider solutions including improved communications.
Aspen Pharmacare, Besins-Healthcare, Gedeon Richter, Novartis, Novo Nordisk, Orion, Pfizer, Theramex, Viatris, and representatives from community pharmacies were
part of the meeting.
As the government confirmed its intention to work with industry to do what is necessary to fix the HRT supply issue, Javis said he wanted to understand the issues
facing suppliers and what can be done to address them.
"We will leave no stone unturned in our national mission to boost supply of HRT. Along with appointing Madelaine McTernan as head of the HRT supply taskforce to implement lessons learned from the pandemic, and ensuring prescriptions are issued in shorter cycles for now, we are working collectively with the sector to urgently resolve this issue," he commented.
The Association of Independent Multiple Pharmacies (AIMp) said the meeting discussed 'why we got into this position' and the way forward.
The General Pharmaceutical Council (GPhC) has urged health and care professionals to meet relevant regulatory standards amidst the shortage of GLP-1 receptor
agonists (GLP-1 RAs).
The council said: "We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs). We know that
these are being widely prescribed for weight loss purposes and in some cases prescribed off-label."
"We recognise the adverse impact that shortages and supply chain issues can have on patients, the public and wider health and care teams.
The Council understands that health and care professionals are using their professional judgement and making decisions in challenging situations, balancing a range
of factors such as individual patient needs, wider public health and pressures and limitations on available resources such as medicines shortages or other supply
chain issues.
Department of Health and Social Care (DHSC) has issued a supply notification for Varicella vaccine (live) powder and solvent for suspension/solution for
injection 0.5ml vials (Varivax and Varilrix) until mid-October.
AAH have put quotas in place for GPs to limit the ordering of Varilrix and safeguard supplies during this shortage. To override this quota or obtain stock in any
other primary care setting (including community pharmacy) a prescription will be required.
To obtain stock through the prescription validation system pharmacy will have to contact AAH Quota Management Customer Care team:
Online https://www.aah.co.uk/s/quotarequest or by logging into AAH Point https://www.aah.co.uk/s/signin then choose Additional Services and select Quotas.
The pharmacy should follow the steps and fill in the required information including their email address.
The pharmacy can also call: 0344 561 8899 and select option 3 (quota)
The pharmacy will need to have the prescription details available
The AAH team will review the request and follow the guidance provided below to validate the prescription and approve the order.
Pharmacists in the UK are reporting significant shortages of a common antibiotic used to treat whooping cough (pertussis), amid rising cases of this bacterial
infection.
Dr. Leyla Hannbeck, chief executive of the Independent Pharmacies Association (IPA), told BBC Radio 4's Today programme that clarithromycin, one of the key
antibiotics for treating whooping cough in children, is "completely out of stock."
Clarithromycin is an antibiotic commonly recommended for babies and infants under the age of 1 month.
Dr. Leyla said that as pharmacies cannot get the antibiotic, they are being forced to turn patients away or send them back to their doctors to have their
prescriptions changed to azithromycin or other antibiotics for treating whooping cough.
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Salazopyrin EN-Tabs 500 mg due to ongoing shortage of the medicine.
With SSP014 in place from today (November 26), for every prescription one Sulfasalazine 500mg gastro-resistant (GR) tablet will be supplied.
This SSP will expire on December 20, 2021, and PSNC will update contractors in case of any change.
PSNC has advised pharmacists to notify the patient's prescriber while supplying in accordance with this SSP.
Besides, the supervising pharmacist should refer back to the prescriber if a non-chewable atorvastatin tablet would not be appropriate for the patient.
The Company Chemists Association (CCA)'s workforce finding showed that by 2024 eight years' worth of growth of the pharmacist workforce will have been
funnelled away from community pharmacies.
"In 2019, when NHS leaders realised they were unable to find enough GPs to meet the public's needs, they hastily decided to recruit pharmacists and other
healthcare professionals to fill the gaps. This was implemented without any corresponding efforts to increase the supply of pharmacists, creating huge shortages,"
said CCA.
"The bulk of the NHS's recruitment drive was paid for using additional money ringfenced by the NHS - the £2.4bn Additional Roles Reimbursement Scheme (ARRS). We
estimate over the life course of ARRS funding (2019-2024), the equivalent of eight years of growth in the number of pharmacists in England will have been funnelled
directly into primary care at the expense of other sectors.
At the current rate, CCA estimate that community pharmacy will have experienced the equivalent of three fallow years by 2024.
To ensure the pharmacy network is protected and able to take pressure off other parts of the NHS, there are several urgent measures which must be implemented.
Countering the impact of primary care recruitment: Community pharmacists should be commissioned to provide 'packages of care' on behalf of GPs, rather than taking
pharmacists away from accessible high street settings.
In response to significant ongoing disruptions in the supply of certain Quetiapine tablet strengths, the Department of Health and Social Care (DHSC) on Tuesday
issued nine new Serious Shortage Protocols (SSPs), with immediate effect.
These measures aim to ensure the continued availability of quetiapine, an essential medication for managing schizophrenia and bipolar disorder.
Under the new SSPs, community pharmacists are allowed to consider different options to manage the shortage of the three strengths of quetiapine tablets affected
by ongoing supply disruptions: quetiapine 300mg tablets, quetiapine 200mg tablets, and quetiapine 150mg tablets.
Depending on the prescribed quantity of the affected quetiapine tablet, pharmacists can either supply a reduced quantity of the same quetiapine tablet or
substitute with an alternative strength or provide a reduced quantity of a specific alternative product.
The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has
raised concerns within the healthcare community.
This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024.
Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in
managing conditions like attention deficit hyperactivity disorder (ADHD).
However, the scarcity of these specific strengths poses challenges for patients reliant on this medication.
Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including
the UK, the US and Australia.
Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand,
potentially resulting in treatment interruptions for patients.
Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry,
which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK.
The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its
investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout
each module.
A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am.
NPA calls for funding to boost pharmacy resilience
Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health
services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.
Boots UK is set to start recruiting for a new superintendent pharmacist as Marc Donovan moved into a new role.
The company announced the appointment of Anne Higgins as the new pharmacy director for Boots UK. A Boots veteran for 25 years, she has been in the role of director
for stores for more than two years since starting her journey as a pre-register pharmacist in July 1997.
Marc Donovan will be moving into the new role of director of healthcare development and public affairs for Boots. Earlier this year Donovan was appointed the Order
of the British Empire (OBE) "for services to pharmacy" in the Queen's Birthday Honours list.
Donovan and Higgins will be reporting to Jamie Kerruish, the director of healthcare at Boots UK.
A Boots spokesperson told Pharmacy Business: "We will be recruiting for a new superintendent pharmacist and once this appointment is made, Marc will hand over his
superintendent responsibilities"
In the parliamentary drop-in-event hosted by Community Pharmacy England last week, Members of Parliament (MPs) questioned the Health Secretary on the rising
issue of medicines supply.
"Eighteen community pharmacists in my constituency are reporting challenges on medicine supplies. What more is the Minister going to do to get a grip of this
situation?", Mike Amesbury MP for Weaver Vale, who was present at the event last week, asked the Health Secretary.
In his response, the Health Secretary, Steve Barclay MP said: "We have a long-standing team in the Department focused on medical supplies, which are a continual
issue; as a matter of routine business, there are often challenges in that area."
The Shadow Pharmacy Minister, Karin Smyth MP, also asked: "People across the country rely on local, accessible pharmacies, but whether it is high street closures
or supply problems leading to the absurd situation where women are phoning or visiting multiple pharmacies for a prescribed dose of hormone replacement therapy and
other drugs…They have repeatedly announced plans to expand the role of community pharmacies but have failed to update legislation that could possibly help. … Why
will they not do so?
Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most
common cold and flu medicine."
She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain
killers - particularly the ones that are soluble."
Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it."
"The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making
sure that they use the relevant products to manage the symptoms.
As whooping cough cases rise sharply across the UK, the NHS has reactivated the serious shortage protocols (SSPs) for clarithromycin - a commonly prescribed
antibiotic to treat this bacterial infection.
Pharmacy bodies had recently warned that community pharmacies were struggling to obtain source clarithromycin for patients.
Two SSPs, covering clarithromycin 125mg/5mL and 250mg/5mL oral suspensions, were reactivated on 22 May 2024, and extended until 21 June 2024.
These protocols state that for every 5mL of clarithromycin 125mg/5mL oral suspension, pharmacy contractors must supply 2.5mL of clarithromycin 250mg/5mL oral
suspension; and for every 5mL of clarithromycin 250mg/5mL oral suspension, one clarithromycin 250mg tablet must be supplied.
The SSPs apply to cross-border prescriptions, both NHS and private.
The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about
the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues.
NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that
salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024.
As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers.
It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.
While Northern Irish business groups has welcomed the certainty a new EU-UK deal on post-Brexit trade rules for the region provided, the pharmaceutical
industry too has expressed cautious optimism.
In his speech on the Windsor Framework on Monday (February 28) Prime Minister Rishi Sunak said the agreement "delivers a landmark settlement on medicines".
"From now on, drugs approved for use by the UK's medicines regulator will be automatically available in every pharmacy and hospital in Northern Ireland," he
announced.
The National Pharmacy Association's Northern Ireland manager Anne McAlister expressed a sense of cautious optimism.
She said: "While the devil may yet be in the detail, the Windsor Framework would appear to be good news for pharmacies in Northern Ireland. It seems to address
the main concerns we have expressed about medicines supplies to NI, but we want to examine the small print to ensure the new arrangements meet the needs of our
members and the patients they serve.